Kelvin Cooper, PhD, is chief executive officer of Lakewood-Amedex Biotherapeutics, where he leads the development of novel antimicrobial therapies for serious drug-resistant bacterial infections. His career spans biotechnology entrepreneurship, infectious diseases, commercialization, and translational medicine. He has focused on expanding treatment options for patients with difficult-to-treat bacterial infections and on the scientific, commercial, and policy conditions needed to sustain antibacterial innovation.